Wellington Management Group’s ADC Therapeutics ADCT Stock Holding History
Bought
Maintained
Sold
Other funds holding ADCT
RG
TCM
PM
EAM
NCM
Wellington Management Group's ADCT Position: Q1 2026 in Review
Wellington Management Group increased its ADC Therapeutics (ADCT) stake by 8.5% in Q1 2026, buying an estimated $71.6K and bringing the position to 231,064 shares worth $866K. The position accounts for ﹤0.01% of the portfolio, ranked #1701.
Wellington Management Group first reported a position in ADCT in Q3 2024 and has held it in 5 quarters since. The position peaked at $1M in Q3 2025. 118 funds tracked by Wall St. Rank hold ADCT as of Q1 2026.
- Wellington Management Group held 231,064 shares of ADC Therapeutics worth $866K as of Q1 2026.
- Wellington Management Group bought 18,149 ADC Therapeutics shares in Q1 2026, an estimated $71.6K.
- ADC Therapeutics made up ﹤0.01% of Wellington Management Group's portfolio in Q1 2026, its #1701 holding.
- Wellington Management Group first reported a position in ADC Therapeutics in Q3 2024 and has held it in 5 quarters since.
- Wellington Management Group's ADC Therapeutics position peaked at $1M in Q3 2025.
- 118 funds tracked by Wall St. Rank held ADC Therapeutics as of Q1 2026.
Based on Wellington Management Group's 13F filing for Q1 2026, filed 15 May 2026.